Aggressive Systemic Mastocytosis clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • (Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis

    open to eligible people ages 18 years and up

    This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

    at UCLA

Our lead scientists for Aggressive Systemic Mastocytosis research studies include .

Last updated: